In addition, prospective studies are warranted to confirm the role of PI-9 in tumor-associated immunosuppression, as well as pre-clinical and clinical investigations, to potentially develop innovative strategies targeting the activity of PI-9 in BC. This evidence concerns the gene SERPINB9 and breast cancer.